JPWO2019195452A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019195452A5 JPWO2019195452A5 JP2020554172A JP2020554172A JPWO2019195452A5 JP WO2019195452 A5 JPWO2019195452 A5 JP WO2019195452A5 JP 2020554172 A JP2020554172 A JP 2020554172A JP 2020554172 A JP2020554172 A JP 2020554172A JP WO2019195452 A5 JPWO2019195452 A5 JP WO2019195452A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- less
- antibody
- antigen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 38
- 108090001123 antibodies Proteins 0.000 claims 38
- 230000027455 binding Effects 0.000 claims 35
- 239000000427 antigen Substances 0.000 claims 29
- 102000038129 antigens Human genes 0.000 claims 29
- 108091007172 antigens Proteins 0.000 claims 29
- 108010045030 monoclonal antibodies Proteins 0.000 claims 24
- 102000005614 monoclonal antibodies Human genes 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 12
- 210000004027 cells Anatomy 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 101700056583 CD27 Proteins 0.000 claims 9
- 102100019459 CD27 Human genes 0.000 claims 9
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 7
- 101700017377 CD70 Proteins 0.000 claims 5
- 102100005830 CD70 Human genes 0.000 claims 5
- 101700086956 IFNG Proteins 0.000 claims 5
- 102100016020 IFNG Human genes 0.000 claims 5
- 108010027440 Immunoconjugates Proteins 0.000 claims 5
- 102000018748 Immunoconjugates Human genes 0.000 claims 5
- 101710040448 TNFRSF4 Proteins 0.000 claims 5
- 102100013135 TNFRSF4 Human genes 0.000 claims 5
- 102100009537 TNFRSF9 Human genes 0.000 claims 5
- 101710040535 TNFRSF9 Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000000684 flow cytometry Methods 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 230000028327 secretion Effects 0.000 claims 5
- 210000004881 tumor cells Anatomy 0.000 claims 5
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 4
- 102100008790 TNFRSF14 Human genes 0.000 claims 4
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 claims 4
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 210000001519 tissues Anatomy 0.000 claims 4
- 101710039842 ADORA2A Proteins 0.000 claims 3
- 102100009333 BTLA Human genes 0.000 claims 3
- 101700047069 BTLA Proteins 0.000 claims 3
- 102100000188 CD244 Human genes 0.000 claims 3
- 101700000388 CD244 Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 102000002698 KIR Receptors Human genes 0.000 claims 3
- 108010043610 KIR Receptors Proteins 0.000 claims 3
- 102100019596 KLRG1 Human genes 0.000 claims 3
- 101700018962 KLRG1 Proteins 0.000 claims 3
- 102100017213 LAG3 Human genes 0.000 claims 3
- 108060004270 LAG3 Proteins 0.000 claims 3
- 210000004185 Liver Anatomy 0.000 claims 3
- 101700067074 MAPK Proteins 0.000 claims 3
- 101710041325 MAPKAPK2 Proteins 0.000 claims 3
- 108010057466 NF-kappa B Proteins 0.000 claims 3
- 102100002692 NFKB1 Human genes 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 101700052319 TIGIT Proteins 0.000 claims 3
- 102100006047 TIGIT Human genes 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- -1 nibolumab Proteins 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 101710024887 rl Proteins 0.000 claims 3
- 101700045897 spk-1 Proteins 0.000 claims 3
- 210000004100 Adrenal Glands Anatomy 0.000 claims 2
- 229950002916 Avelumab Drugs 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 2
- 101710040446 CD40 Proteins 0.000 claims 2
- 102100013137 CD40 Human genes 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 210000003169 Central Nervous System Anatomy 0.000 claims 2
- 210000001638 Cerebellum Anatomy 0.000 claims 2
- 210000004720 Cerebrum Anatomy 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 229950009791 Durvalumab Drugs 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 210000002216 Heart Anatomy 0.000 claims 2
- 102000018358 Immunoglobulins Human genes 0.000 claims 2
- 108060003951 Immunoglobulins Proteins 0.000 claims 2
- 210000003734 Kidney Anatomy 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 108090000393 Muromonab-CD3 Proteins 0.000 claims 2
- 108010019706 Nivolumab Proteins 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 210000000496 Pancreas Anatomy 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 210000000578 Peripheral Nerves Anatomy 0.000 claims 2
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 210000003635 Pituitary Gland Anatomy 0.000 claims 2
- 210000002826 Placenta Anatomy 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 210000002307 Prostate Anatomy 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 102100012980 TNFRSF10B Human genes 0.000 claims 2
- 101710030970 TNFRSF10B Proteins 0.000 claims 2
- 101710040533 TNFRSF8 Proteins 0.000 claims 2
- 102100009538 TNFRSF8 Human genes 0.000 claims 2
- 210000001550 Testis Anatomy 0.000 claims 2
- 210000001685 Thyroid Gland Anatomy 0.000 claims 2
- 210000001635 Urinary Tract Anatomy 0.000 claims 2
- 210000004291 Uterus Anatomy 0.000 claims 2
- 101710036075 VSIR Proteins 0.000 claims 2
- 102100015314 VSIR Human genes 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 108010072668 atezolizumab Proteins 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 230000003190 augmentative Effects 0.000 claims 2
- 108010010826 avelumab Proteins 0.000 claims 2
- 238000004166 bioassay Methods 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000020411 cell activation Effects 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 108091006028 chimera Proteins 0.000 claims 2
- 230000000139 costimulatory Effects 0.000 claims 2
- 108010016436 durvalumab Proteins 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 230000002147 killing Effects 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 210000003071 memory T lymphocyte Anatomy 0.000 claims 2
- GIYXAJPCNFJEHY-UHFFFAOYSA-N methyl-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]azanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 108010026276 pembrolizumab Proteins 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 101700027111 3SA0 Proteins 0.000 claims 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- 108010090685 BMS-936559 Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 101710007023 ESAG4 Proteins 0.000 claims 1
- 231100000655 Enterotoxin Toxicity 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 210000004392 Genitalia Anatomy 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 210000004408 Hybridomas Anatomy 0.000 claims 1
- 206010020630 Hypergammaglobulinaemia Diseases 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 210000000987 Immune System Anatomy 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 210000001616 Monocytes Anatomy 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108010002487 Thomsen-Friedenreich antibodies Proteins 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 206010046885 Vaginal cancer Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002022 anti-cellular Effects 0.000 claims 1
- 230000003602 anti-herpes Effects 0.000 claims 1
- 230000000781 anti-lymphocytic Effects 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000003969 blast cell Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000005216 brain cancer Diseases 0.000 claims 1
- 239000001390 capsicum minimum Substances 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 101700067609 ctx Proteins 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 230000029578 entry into host Effects 0.000 claims 1
- 210000002919 epithelial cells Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000008808 fibrosarcoma Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 102000025599 immune receptors Human genes 0.000 claims 1
- 108091008191 immune receptors Proteins 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000000503 lectinlike Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 200000000023 metastatic cancer Diseases 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 201000005746 pituitary adenoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000000750 progressive Effects 0.000 claims 1
- 101700032180 psaA Proteins 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 101710011036 stiI Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000002588 toxic Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652790P | 2018-04-04 | 2018-04-04 | |
| US62/652,790 | 2018-04-04 | ||
| PCT/US2019/025623 WO2019195452A1 (en) | 2018-04-04 | 2019-04-03 | Anti-cd27 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021520201A JP2021520201A (ja) | 2021-08-19 |
| JPWO2019195452A5 true JPWO2019195452A5 (zh) | 2022-04-12 |
Family
ID=66175569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554172A Pending JP2021520201A (ja) | 2018-04-04 | 2019-04-03 | 抗ｃｄ２７抗体およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12110337B2 (zh) |
| EP (1) | EP3774903A1 (zh) |
| JP (1) | JP2021520201A (zh) |
| KR (1) | KR20200140315A (zh) |
| CN (1) | CN112292399A (zh) |
| WO (1) | WO2019195452A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101339628B1 (ko) * | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| US20230242624A1 (en) | 2020-06-02 | 2023-08-03 | Neurimmune Ag | HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) |
| JP2023535610A (ja) * | 2020-07-28 | 2023-08-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ガンを予防及び処置するための方法及び組成物 |
| CN112194723B (zh) * | 2020-09-25 | 2021-09-21 | 广州百吉生物制药有限公司 | 一种免疫细胞在治疗癌症中应用 |
| TW202328192A (zh) | 2021-09-06 | 2023-07-16 | 荷蘭商珍美寶公司 | 能結合ｃｄ２７之抗體、彼之變異體及彼等之用途 |
| AU2023236289A1 (en) | 2022-03-15 | 2024-08-15 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| WO2023218051A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| HUE049647T2 (hu) | 2009-11-24 | 2020-09-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
| US9169325B2 (en) * | 2010-04-13 | 2015-10-27 | Celldex Therapeutics, Inc. | Antibodies that bind human CD27 and uses thereof |
| CA2804550C (en) * | 2010-07-09 | 2021-01-05 | Bionovion Holding B.V. | Agonistic antibody to cd27 |
| RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
| SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| CA2867299C (en) * | 2012-03-15 | 2019-08-27 | John Chen | Human anti-cd27 antibodies, methods, and uses |
| BR112014028826B1 (pt) | 2012-05-15 | 2024-04-30 | Bristol-Myers Squibb Company | Uso de nivolumab ou pembrolizumabe |
| KR102284247B1 (ko) | 2012-05-31 | 2021-08-03 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| CA2910278C (en) | 2013-05-02 | 2021-09-28 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
| EP3004169B1 (en) | 2013-05-31 | 2023-03-22 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| ES2927567T3 (es) | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| JP6502959B2 (ja) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2016081748A2 (en) * | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
| EP3237446B1 (en) | 2014-12-22 | 2021-05-05 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| WO2016145085A2 (en) * | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| BR112017021688A2 (pt) * | 2015-04-17 | 2018-08-14 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo |
| US10696745B2 (en) | 2015-06-11 | 2020-06-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Anti-PD-L1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP3334763B1 (en) | 2015-08-11 | 2024-08-07 | WuXi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN107949573B (zh) | 2015-09-01 | 2022-05-03 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| MX2018007089A (es) | 2015-12-14 | 2019-01-30 | Macrogenics Inc | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. |
| KR20180101417A (ko) | 2016-01-11 | 2018-09-12 | 아르모 바이오사이언시스 인코포레이티드 | 항원-특이적 cd8+ t 세포의 제조에서 인터루킨-10 및 이의 사용 방법 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| JOP20190055A1 (ar) * | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
-
2019
- 2019-04-03 EP EP19717731.4A patent/EP3774903A1/en active Pending
- 2019-04-03 KR KR1020207031468A patent/KR20200140315A/ko active Search and Examination
- 2019-04-03 WO PCT/US2019/025623 patent/WO2019195452A1/en unknown
- 2019-04-03 CN CN201980024528.3A patent/CN112292399A/zh active Pending
- 2019-04-03 US US17/045,143 patent/US12110337B2/en active Active
- 2019-04-03 JP JP2020554172A patent/JP2021520201A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180360962A1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| JP2020501531A5 (zh) | ||
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP2021506244A5 (zh) | ||
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2019536470A5 (zh) | ||
| JP2019524693A5 (zh) | ||
| JP2019500892A5 (zh) | ||
| JP2019511212A5 (zh) | ||
| JPWO2021194942A5 (zh) | ||
| JP2021520201A (ja) | 抗ｃｄ２７抗体およびその使用 | |
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JP7560508B2 (ja) | がん免疫治療における胃腸の免疫関連有害事象の治療方法 | |
| JPWO2019226973A5 (zh) | ||
| JP2018521959A (ja) | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション | |
| WO2019057792A1 (en) | CD40 ANTIBODY AGONISTS | |
| JPWO2019195452A5 (zh) | ||
| JPWO2021011885A5 (zh) | ||
| JPWO2020076799A5 (zh) | ||
| JP7392145B2 (ja) | 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム | |
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| JP2024512382A (ja) | Ｐｄ－１標的化ｉｌ－２バリアント免疫コンジュゲートと抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体の併用療法 | |
| JP2023542212A (ja) | Ｔ細胞二重特異性抗体に関連する有害作用の予防又は緩和 | |
| JPWO2020006374A5 (zh) | ||
| JPWO2019219064A5 (zh) |